Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
Ardelyx, Inc. (Nasdaq: ARDX) will hold a conference call on November 3, 2022, at 4:30 p.m. Eastern Time to discuss its third quarter 2022 financial results and provide a business overview. This call can be accessed by dialing (866) 374-5140 domestically or (404) 400-0571 internationally, with a pin code of 79680409#. The audio will also be webcasted and archived for 30 days on the company's website. Ardelyx’s first product, IBSRELA®, is available in the U.S. and Canada, and it is developing additional medicines to address unmet medical needs.
- None.
- None.
- Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., Oct. 27, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time to review third quarter 2022 financial results and provide a business overview.
To participate in the conference call, please dial (866) 374-5140 (domestic) or (404) 400-0571 (international) and enter the pin 79680409#. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-report-third-quarter-2022-financial-results-on-november-3-2022-301660882.html
SOURCE Ardelyx
FAQ
When will Ardelyx report its third quarter 2022 financial results?
What time is the Ardelyx conference call scheduled for?
How can I participate in the Ardelyx conference call?
Where can I find the webcast of the Ardelyx conference call?
